Product Description: Sampeginterferon beta-1a (BCD-054) is a pegylated IFNβ-1a. Sampeginterferon beta-1a can be used for research against remitting multiple sclerosis[1][2].
Formula: N/A
References: [1]Boyko AN, et al. Novyĭ pegilirovannyĭ interferon beta-1a (sampéginterferon beta-1a, BCD-054) v terapii remittiruiushchego rasseiannogo skleroza [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):100-109. Russian. /[2]Boyko A N. Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)[J]. Neurology, Neuropsychiatry, Psychosomatics, 2022, 14(1S): 34-37.
CAS Number: 1796570-07-4
Molecular Weight: N/A
Research Area: Others
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
